Turan Tufan

Dr. Turan Tufan

Washington University in St. Louis, St Louis, USA
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2017 in Nature Methods
Verified
Journal Article
Closed access
CKCem Kuscu
Cem Kuscu
MPMahmut Parlak
Mahmut Parlak
Turan TufanTuran Tufan
Turan Tufan
JYJiekun Yang
Jiekun Yang
KSKarol Szlachta
Karol Szlachta
MAMazhar Adli
Mazhar Adli

22 December 2022 in Cell
Verified
Journal Article
Closed access
SMSho Morioka
Sho Morioka
DKDaiki Kajioka
Daiki Kajioka
YYYusuke Yamaoka
Yusuke Yamaoka
RERochelle M. Ellison
Rochelle M. Ellison
Turan TufanTuran Tufan
Turan Tufan
KRKodi S. Ravichandran
Kodi S. Ravichandran

15 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKarol Szlachta
Karol Szlachta
CKCem Kuscu
Cem Kuscu
Turan TufanTuran Tufan
Turan Tufan
SASara J. Adair
Sara J. Adair
SSStephen Shang
Stephen Shang
MAMazhar Adli
Mazhar Adli
Predicting the response and identifying additional targets that will improve the efficacy of chemotherapy is a major goal in cancer research. Through large-scale in vivo and in vitro CRISPR knockout screens in pancreatic ductal adenocarcinoma cells, we identified genes whose genetic deletion or pharmacologic inhibition synergistically increase the cytotoxicity of MEK signaling inhibitors. Furthermore, we show that CRISPR viability scores combined with basal gene expression levels could model global cellular responses to the drug treatment. We develop drug response evaluation by in vivo CRISPR screening (DREBIC) method and validated its efficacy using large-scale experimental data from independent experiments. Comparative analyses demonstrate that DREBIC predicts drug response in cancer cells from a wide range of tissues with high accuracy and identifies therapeutic vulnerabilities of cancer-causing mutations to MEK inhibitors in various cancer types.

28 April 2016 in Neurotoxicity Research
Verified
Journal Article
Closed access
PDF file
MRMuhammad Ummear Raza
Muhammad Ummear Raza
Turan TufanTuran Tufan
Turan Tufan
YWYan Wang
Yan Wang
CHChristopher Hill
Christopher Hill
MZMeng-Yang Zhu
Meng-Yang Zhu

13 September 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SSStephen Shang
Stephen Shang
JYJiekun Yang
Jiekun Yang
AJAmir A. Jazaeri
Amir A. Jazaeri
ADAlexander James Duval
Alexander James Duval
Turan TufanTuran Tufan
Turan Tufan
MAMazhar Adli
Mazhar Adli
Chemoresistance is driven by unique regulatory networks in the genome that are distinct from those necessary for cancer development. Here, we investigate the contribution of enhancer elements to cisplatin resistance in ovarian cancers. Epigenome profiling of multiple cellular models of chemoresistance identified unique sets of distal enhancers, super-enhancers (SE), and their gene targets that coordinate and maintain the transcriptional program of the platinum-resistant state in ovarian cancer. Pharmacologic inhibition of distal enhancers through small-molecule epigenetic inhibitors suppressed the expression of their target genes and restored cisplatin sensitivity in vitro and in vivo. In addition to known drivers of chemoresistance, our findings identified SOX9 as a critical SE-regulated transcription factor that plays a critical role in acquiring and maintaining the chemoresistant state in ovarian cancer. The approach and findings presented here suggest that integrative analysis of epigenome and transcriptional programs could identify targetable key drivers of chemoresistance in cancers. Significance: Integrative genome-wide epigenomic and transcriptomic analyses of platinum-sensitive and -resistant ovarian lines identify key distal regulatory regions and associated master regulator transcription factors that can be targeted by small-molecule epigenetic inhibitors.

2 October 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MMMaria Florencia Martinez
Maria Florencia Martinez
SMSilvia Medrano
Silvia Medrano
EBEvan A Brown
Evan A Brown
Turan TufanTuran Tufan
Turan Tufan
SSStephen Shang
Stephen Shang
RGR Ariel Gomez
R Ariel Gomez
Renin cells are crucial for survival — they control fluid-electrolyte and blood pressure homeostasis, vascular development, regeneration, and oxygen delivery to tissues. During embryonic development, renin cells are progenitors for multiple cell types that retain the memory of the renin phenotype. When there is a threat to survival, those descendants are transformed and reenact the renin phenotype to restore homeostasis. We tested the hypothesis that the molecular memory of the renin phenotype resides in unique regions and states of these cells’ chromatin. Using renin cells at various stages of stimulation, we identified regions in the genome where the chromatin is open for transcription, mapped histone modifications characteristic of active enhancers such as H3K27ac, and tracked deposition of transcriptional activators such as Med1, whose deletion results in ablation of renin expression and low blood pressure. Using the rank ordering of super-enhancers, epigenetic rewriting, and enhancer deletion analysis, we found that renin cells harbor a unique set of super-enhancers that determine their identity. The most prominent renin super-enhancer may act as a chromatin sensor of signals that convey the physiologic status of the organism, and is responsible for the transformation of renin cell descendants to the renin phenotype, a fundamental process to ensure homeostasis.